Project Details
Description
Medication review (MR) counteract the use of inappropriate medication (IM),
which is a common problem among the elderly. People living with dementia
(PWD) are especially vulnerable to IM and MR is thus crucial for this group.
The Swedish National Board of Health and Welfare (NBHW) have specific
regulations on who should receive a MR and when, i.e., patients ≥75 years of
age or having ≥5 medications should receive an MR in the primary care, and
while admitted to the hospital, living in assisted home care, nursing home, or
assessed by a physician.
Howerver, Swedish healthcare regions have their own rules and regulation
regarding MR. For example, in Skåne the age limit is ≥65; in Västra Götaland
no limit on the number of drugs; in Östergötland no limit on either age or
number of drugs. However, research is limited on which MR model is (most)
effective, cost-effective and contributes to a reduction in health inequality
among PWD.
We will create a database linking several national and local registers such as
the Patient register, Pharmaceutical register, and regional databases on
healthcare utilization. The study sample includes all persons with a dementia
diagnosis in the selected regions from 2013 (the year the MR guidelines were
introduced by the NBHW) to 2022. A comparison group from the general
population will be created, matched on age, sex, and area of residence. We
will employ panel data analysis methods that exploit the longitudinal nature of
the data.
which is a common problem among the elderly. People living with dementia
(PWD) are especially vulnerable to IM and MR is thus crucial for this group.
The Swedish National Board of Health and Welfare (NBHW) have specific
regulations on who should receive a MR and when, i.e., patients ≥75 years of
age or having ≥5 medications should receive an MR in the primary care, and
while admitted to the hospital, living in assisted home care, nursing home, or
assessed by a physician.
Howerver, Swedish healthcare regions have their own rules and regulation
regarding MR. For example, in Skåne the age limit is ≥65; in Västra Götaland
no limit on the number of drugs; in Östergötland no limit on either age or
number of drugs. However, research is limited on which MR model is (most)
effective, cost-effective and contributes to a reduction in health inequality
among PWD.
We will create a database linking several national and local registers such as
the Patient register, Pharmaceutical register, and regional databases on
healthcare utilization. The study sample includes all persons with a dementia
diagnosis in the selected regions from 2013 (the year the MR guidelines were
introduced by the NBHW) to 2022. A comparison group from the general
population will be created, matched on age, sex, and area of residence. We
will employ panel data analysis methods that exploit the longitudinal nature of
the data.
| Status | Active |
|---|---|
| Effective start/end date | 2023/12/01 → 2027/12/31 |
Funding
- Swedish Research Council
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):
Subject classification (UKÄ)
- Health Care Service and Management, Health Policy and Services and Health Economy